Key Gaps in Malaria and Emerging Infectious Disease Control - Priorities for a Regional Response Dr Eva Christophel, in collaboration with relevant units and the SEARO WHO Regional Office for the Western Pacific, Manila, Philippines APLMA Regional Financing for Malaria Task Force (RFMTF), Hong Kong, May 12, 2014
43
Embed
Key Gaps in Malaria and Emerging Infectious Disease Control
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Key Gaps in Malaria and Emerging Infectious Disease Control -
Priorities for a Regional Response
Dr Eva Christophel, in collaboration with relevant units and the SEARO
WHO Regional Office for the Western Pacific, Manila, Philippines
APLMA Regional Financing for Malaria Task Force (RFMTF), Hong Kong, May 12, 2014
2
Outline of Presentation
Burden of major communicable diseases in the Region, key gaps
Malaria: Threats to controlling and eliminating malaria in Asia Pacific, and opportunities.
Priorities for a Regional Response
3
Malaria: 20 Endemic countries in WP and SEA Regions
SEAR countries
WPR countries
2012 (WMR 2013)
SEAR WPR Afghanistan,Pakistan
Total
Estimated # malaria cases
26.8 mio(21.7-32.5)
1.4 mio(1.2-1.7 mio)
376,7683,485,366
32.1 mio
Estimated # malaria deaths
42 000(25 000-60
000)
3 500(2 100 – 5
200)
261970
47,496
Population at risk (high and low transmission areas)
1.6 billion 711 million 16,030,688102,121,263
2.4 billion
4
Tuberculosis: Distribution of Prevalent TB Patients, by Region
Source: Global Tuberculosis Control 2013, WHO4
2012 Estimates SEAR WPR
TB Cases (all forms) 3.4 mio 1.6 mio
TB Deaths 450,000 110,000
Multi-drug resistant TB 90,000 74,000
HIV-associated TB 170,000 24,000
5
1. Current diagnostic algorithms are not sensitive enough to detect TB patients early;
2. TB concentrates among high-risk and socially vulnerable populations who are difficult to reach;
3. Multi-drug resistant TB: only a small fraction of MDR-TB patients are diagnosed, ensuring treatment is also a challenge;
4. High percentage of external funding, esp through the Global Fund. Donor investment is shrinking in the Region, which threatens sustainability of programmes.
Tuberculosis: Challenges
6
Tuberculosis: Financial Gap WPR
In the WPR, national TB programmes report a funding gap of over USD 200 million per year.
7
Source: Prepared by www.aidsdatahub.org based on UNAIDS HIV Estimates 2012 for UNAIDS.(2013). Global Report: UNAIDS Report on the Global AIDS Epidemic 2013.
HIV: Increase in Domestic funding to make up for the Levelling off of International Financing
Source: UNAIDS estimates 2012
Resources available for AIDS response in Asia and the Pacific, low-and middle-income countries (LMIC)
9
HIV: Challenges in Financing HIV programmes
Heavily reliant on donor funding for low and middle income countries, particularly Cambodia (89%), Lao PDR (93%) and Viet Nam (83%). Government should increase their domestic public HIV spending as GDP per capita rises;
Not enough is spent on key populations prevention programmes, e.g. spending on prevention for key populations accounts for only 24% of AIDS spending in Asia and the Pacific (2009-2012).
Moreover, prevention spending on key populations is heavily dependent on international financing sources.
10
Hepatitis B: Distribution of estimated Number of annual Deaths, by Region
Courtesy of IHME – Global Burden of Disease Study
11
The Global Hepatitis Action Plan
11
Axis 2: Data for policy and action
Axis 1: Partnerships, resource mobilization and communication
Axis 3: Prevention of virus transmission
Axis 4: Screening, care and treatment
12
Hepatitis: Gaps and Challenges
• Low levels of awareness, advocacy, and financial engagement from national governments
• Lack of data is a barrier to country-level dialogue and engagement
• Progress made in prevention, especially HBV immunization, but high coverage of birth dose vaccination remains a challenge in many countries
• Remarkable advances in hepatitis treatment options, but equitable access to quality and affordable diagnostics and medicines still far for many countries.
Traditional Polio Global eradication GAVI for inactivated polio vaccine (IPV)
Traditional Diphtheria-Pertussis-Tetanus (DPT)
Traditional Measles Regional elimination
New Hepatitis B Regional control GAVI*
New Hemophilus influenzae type b (Hib)
GAVI*
New Human Papillomavirus (HPV)
GAVI*
New Japanese encephalitis Regional control (proposed) GAVI*
New Pneumococcal GAVI*
New Rotavirus GAVI*
New Rubella Regional control(Regional elimination proposed)
GAVI*
Support available to GAVI eligible countries and GAVI graduating countries*GAVI eligible countries in the Western Pacific: Cambodia, Lao People’s Democratic Republic, Solomon Islands, Viet Nam
14
Measles: Disease Burden and Trends Measles Cases by Month and Year, WPR, 2008–2013
Progress towards 2012 Measles Elimination Goal:94% reduction in reported measles cases in the Region between 2000 and 2012 when historic low incidence was achieved;
A relative resurgence in measles occurred in the Region in 2013 and 2014 with recent outbreaks in China, Papua New Guinea, the Philippines, and Viet Nam.
15
Measles: Strategies and ChallengesReported measles cases and coverage with first and
second dose of measles vaccine, 1980-2012 An important strategy to achieve measles elimination is high (>95%) coverage with two doses of measles vaccine.
Immunity gaps (pockets of susceptible persons, especially among migrants) allows measles virus to continue spreading
4 (of 37) countries and areas have not yet introduced routine second dose:•Lao People’s Democratic Republic •Papua New Guinea•Solomon Islands•Vanuatu
• Lao PDR:– Overall 2 cases ( 2 deaths) were reported in 2007– Since then, no case has been reported to date
• Viet Nam:– Overall 127 cases ( 64 deaths, CFR 50%) – In 2014, two fatal cases reported
23
EID: Avian Influenza A(H7N9) –Human Cases
24
EID: Distribution of Human Infections with Avian Influenza A(H7N9)
Number of cases
"The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement."
25
EID: Arboviral Disease Outbreaks in Pacific Island Countries and Areas (May 2014)
CHIKV
DENV-?
26
EID: Economic Impact
• SARS• MERS-CoV, Philippines:
o Testing all passengers on-board a plane carrying a MERS-CoV positive case ~ 2 million pesos1
• H7N9 in mainland China:o Outbreaks estimated to
have caused 60 billion yuan loss to the poultry industry (I/II 2013) and at least 40 billion yuan in 20142
• Legally binding international instrument for global public health security, for preventing international spread of disease, enforced 2007
• International commitment for shared responsibilities and collective defence against diseases information sharing!
• Network of national IHR focal points and WHO contact points, 24/7
28
EID: Challenges
• Health security threats continue to occur in unexpected way, if not managed well, resulting in significant health, economic, social and political consequences
• Strong national and international capacities are a MUST for managing unpredictable/uncertain threats
• The Region is NOT sufficiently prepared to cope with severe public health emergencies and disasters
• Investing in health security essential, AND sustaining it equally vital
29
EID: The way forward
• Continue to support to countries in meeting the IHR core capacity requirements through implementation of the Asia Pacific Strategy for Emerging Diseases/APSED (2010). This includes capacity building in surveillance, laboratory, zoonoses, risk communication, PH emergency planning
• Regional strategies, especially APSED, have proven to be valuable tools to support countries to meet IHR core capacity requirements.
• Promote cross-cutting capacities that serve as foundation for all emergency risk management
• Foster regional partnerships for emergency risk management • Respond to major emerging disease outbreaks and
emergencies swiftly and in coordinated way (WHO Emergency Response Framework)
30
Malaria: Progress in the WPR, 2000-2012
Source: World Malaria Report 2013
31
Malaria: Countries projected to achieve >75% decrease in incidence of microscopically confirmed cases by 2015
SEAR WPR
Source: World Malaria Report 2013
• India, Indonesia and Myanmar (SEAR), Papua New Guinea (WPR), Pakistan (EMR) cannot be projected to achieve the 75% decrease by 2015
• In the SEAR, 3/10 countries, and in the WPR, 2/10 are in pre-/elimination phase
32
Malaria: Threats & Opportunities
THREATSLosing the gains and investments made, malaria resurgence
o Shrinking financingo Limited/declining programme capacityo Decreasing government commitment once cases decreaseo Unregulated economic development
Artemisinin resistanceo Health systems issues, e.g pharmaceutical issues (OAMTs,
counterfeit/substand medicines, stockouts, irrational drug use)o Malaria control and elimination services, eg insufficient reach to migrant/mobile
populationso Insufficient engagement of the non-health sector
Malaria: The Global Challenge of Artemisinin Resistance
• Foci identified in five countries in the Greater Mekong Subregion, mainly along international borders
• Artemisinin resistance so far only confirmed in this region
• Containment efforts ongoing since 2008
• Number of detected foci increasing
35
Malaria: Emergency Response Framework
• Emergency response based on strategic recommendations of a joint assessment by development partners
• Aim is to increase coordination, quality and coverage of interventions
• Launched in 2013 in Phnom Penh, Cambodia, where WHO has opened a Regional Hub to coordinate ERAR (supported by the Gates Foundation and Australia)
• Global Fund has committed 100 million USD to combat artemisinin resistance in GMS
• Funding gap was estimated at USD 450 mio/3 years, but will be higher due to recent TEG recommendation to expand Tier 2 throughout GMS
36
Malaria Financing: Domestic Funding for Malaria Control, 2005-2012
Source: World Malaria Report 2013
37
Malaria Financing:Trends in Domestic Funding, Philippines
Increasing government contribution to disease program
*Estimates for 2015 and 2016 are based on a modest anticipated increase of 1% in the annual program budget after 2014. Figures refer to national government funds only.
Source: Philippines Vectorborne Diseases National Programme
38
Malaria Financing: USD per Person at Risk, by WHO Region and Funding Source, 2005–2012
Source: World Malaria Report 2013
39
Malaria Financing: Global Fund Allocations to WPR Countries under New Funding Model
40
Malaria Financing: Malaria Programme Funding Gaps in Solomon Islands, Vanuatu, PNG, based on costed National Strategic Plans
LLINS required to maintain 100% coverage: 5,707,530 Cost (including delivery to end user): $46,202,717Anticipated GF funding (including existing funds - $1,707,841) $23,740,745Anticipated GF funding as % of LLIN component requirement: 51%
Papua New Guinea – LLIN requirements, 2015-2017
41
Conclusions
• Major improvements have been achieved across a range of communicable diseases in the Region, but the CD burden remains significant, disproportionately affecting the poor. Much remains to be done.
• We have effective tools for most diseases. These cannot be sufficiently rolled out, largely because of significant funding gaps, which are increasing due to shrinking external funding to the Region. Despite most of the countries in the Region having moved to middle-income status, these funding gaps currently cannot all be shouldered by national budgets, except in a few.
• Malaria is especially vulnerable to losing the enormous gains and investments made, as it can resurge rapidly once interventions are scaled back prematurely.
• There are many opportunities for regional collaboration (e.g ERAR, ASEAN, IHR/APSED, Interpol) which should be intensified.
42
Priorities for a regional response
1. Mobilize funds to fill the programme gaps. o Prioritize high incidence countries. o Artemisinin resistance containment/elimination, as a regional and global
public good, should receive international financingo Malaria elimination should have significant domestic funds.
2. Use the opportunity of the current revision and costing of National Malaria Strategic Plans in most countries to get detailed analyses of malaria programme requirements (eg commodities, funds), which should be used at regional and global levels.
3. Foster greater collaboration between malaria and other national and regional initiatives, for synergies and cost saving, and document and evaluate this. Including on cross cutting issues such as migrant health.
4. Initiate innovative funding models and pilot and evaluate them. o